CUE on Nasdaq
Cue Biopharma, Inc.
In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases.”5 It is headquartered in Cambridge, United States.2 Its shares trade on Nasdaq under the symbol CUE.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Celularity Inc, Entrada Therapeutics, Inc. or Foghorn Therapeutics Inc., or pick any stock.
- TickerCUE on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersCambridge, United States2
- Incorporated inDE3
- Business address100 Chestnut Street, Suite 300, Somerville, Ma 021433
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300PBW78KZA33WC972
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O National Registered Agents, Inc., 19904 Dover, United States2
- Registered withDivision of Corporations, Department of State, 56107502
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune and inflammatory diseases. Our programs include, but are not limited to, drug product candidates designed to:5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-96.7%Operating margin6
-96.9%Net margin6
195.7%Revenue growth, 20256
-100.6%Return on equity6
-$21.9MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development98¢$37.7M
- Interest0¢$100.0K
- Income tax1¢$500.0K
Out of $27.5M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $27.5M | $9.3M |
| General and administrative | $16.2M | $14.6M |
| Research and development | $37.7M | $36.3M |
| Loss (gain) on fixed asset disposal | $31.0K | -$93.0K |
| Total operating expenses | $54.0M | $50.8M |
| Loss from operations | -$26.6M | -$41.5M |
| Interest income | $807.0K | $1.6M |
| Interest expense | -$357.0K | -$796.0K |
| Total other income, net | $450.0K | $826.0K |
| Loss before provision for income taxes | -$26.1M | -$40.7M |
| Provision for income taxes | -$500.0K | $0 |
| Net loss | -$26.6M | -$40.7M |
| Net loss per common share - basic | -$0.28 | -$0.72 |
| Net loss per common share - diluted | -$0.28 | -$0.72 |
| Weighted average common shares outstanding, basic | 94.7M shares | 56.3M shares |
| Weighted average common shares outstanding, diluted | 94.7M shares | 56.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2025-03-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $27.1M | $22.5M | ||
| Accounts receivable | $5.5M | $945.0K | ||
| Deposits, current portion | $1.1M | $929.0K | ||
| Prepaid expenses and other current assets | $1.3M | $805.0K | ||
| Foreign withholding tax receivable | $1.9M | $0 | ||
| Total current assets | $37.0M | $25.1M | ||
| Property and equipment, net | $241.0K | $471.0K | ||
| Operating lease, right-of-use asset | $4.1M | $4.4M | ||
| Deposits, net of current portion | $666.0K | $2.0M | ||
| Restricted cash | $154.0K | $152.0K | ||
| Other long term assets | $94.0K | $105.0K | ||
| Total assets | $42.2M | $32.2M | ||
| Accounts payable | $3.9M | $2.8M | ||
| Accrued expenses | $1.6M | $2.9M | ||
| Research and development contract liability, current portion | $5.3M | $85.0K | ||
| Operating lease liabilities, net of current portion | $1.9M | $3.5M | ||
| Current portion of long-term debt, net | $0 | $4.3M | ||
| Other current payable | $689.0K | $0 | ||
| Total current liabilities | $13.5M | $13.7M | ||
| Operating lease liabilities, current portion | $2.3M | $1.0M | ||
| Total liabilities | $15.8M | $14.7M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 300,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 96,621,218 and 61,819,101 shares issued and outstanding at December 31, 2025 and 2024, respectively | $97.0K | $62.0K | ||
| Additional paid in capital | $394.8M | $359.3M | ||
| Accumulated deficit | -$368.5M | -$341.9M | ||
| Total stockholders equity | $26.4M | $17.5M | $37.1M | |
| Total liabilities and stockholders equity | $42.2M | $32.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 200.0M shares | ||
| Common stock, shares issued | 96.6M shares | 13.5M shares | 61.8M shares | |
| Common stock, shares outstanding | 96.6M shares | 61.8M shares |
| Period ending | 2025-12-31 | 2025-03-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $27.1M | $22.5M | ||
| Accounts receivable | $5.5M | $945.0K | ||
| Deposits, current portion | $1.1M | $929.0K | ||
| Prepaid expenses and other current assets | $1.3M | $805.0K | ||
| Foreign withholding tax receivable | $1.9M | $0 | ||
| Total current assets | $37.0M | $25.1M | ||
| Property and equipment, net | $241.0K | $471.0K | ||
| Operating lease, right-of-use asset | $4.1M | $4.4M | ||
| Deposits, net of current portion | $666.0K | $2.0M | ||
| Restricted cash | $154.0K | $152.0K | ||
| Other long term assets | $94.0K | $105.0K | ||
| Total assets | $42.2M | $32.2M | ||
| Accounts payable | $3.9M | $2.8M | ||
| Accrued expenses | $1.6M | $2.9M | ||
| Research and development contract liability, current portion | $5.3M | $85.0K | ||
| Operating lease liabilities, net of current portion | $1.9M | $3.5M | ||
| Current portion of long-term debt, net | $0 | $4.3M | ||
| Other current payable | $689.0K | $0 | ||
| Total current liabilities | $13.5M | $13.7M | ||
| Operating lease liabilities, current portion | $2.3M | $1.0M | ||
| Total liabilities | $15.8M | $14.7M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 300,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 96,621,218 and 61,819,101 shares issued and outstanding at December 31, 2025 and 2024, respectively | $97.0K | $62.0K | ||
| Additional paid in capital | $394.8M | $359.3M | ||
| Accumulated deficit | -$368.5M | -$341.9M | ||
| Total stockholders equity | $26.4M | $17.5M | $37.1M | |
| Total liabilities and stockholders equity | $42.2M | $32.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 200.0M shares | ||
| Common stock, shares issued | 96.6M shares | 13.5M shares | 61.8M shares | |
| Common stock, shares outstanding | 96.6M shares | 61.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$26.6M | -$40.7M |
| Depreciation and amortization | $958.0K | $397.0K |
| Stock-based compensation | $4.7M | $6.8M |
| Decrease in the carrying amount of right-of-use assets | $2.5M | $2.0M |
| Amortization of premium/discount on purchased securities | -$212.0K | $0 |
| Loss (gain) on fixed asset disposal | $31.0K | -$93.0K |
| Amortization of debt issuance costs | $37.0K | $37.0K |
| Accretion of final payment of term loan | $130.0K | $130.0K |
| Accounts receivable | -$4.6M | $753.0K |
| Prepaid expenses and other current assets | -$1.1M | $150.0K |
| Deposits | $1.1M | $93.0K |
| Foreign withholding tax receivable | -$1.9M | $0 |
| Other payable | $689.0K | $0 |
| Accounts payable | $1.1M | -$678.0K |
| Accrued expenses | -$1.3M | -$1.2M |
| Research and development contract liability, current portion | $5.2M | -$2.0M |
| Operating lease liability | -$2.6M | -$2.0M |
| Net cash used in operating activities | -$21.7M | -$36.3M |
| Purchases of property and equipment | -$177.0K | -$66.0K |
| Cash received from the sale of property and equipment | $40.0K | $98.0K |
| Purchases of marketable securities | -$16.3M | $0 |
| Redemption of marketable securities | $16.5M | $0 |
| Net cash provided by investing activities | $75.0K | $32.0K |
| Proceeds from ATM offering, net of sales agent commission and fees | $2.5M | $3.4M |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | $28.3M | $10.8M |
| Repayment of term loans | -$4.5M | -$4.0M |
| Issuance of common stock upon exercise of warrants and pre-funded warrants, net | $0 | $18.0K |
| Net cash provided by financing activities | $26.3M | $10.2M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $4.7M | -$26.1M |
| Cash paid for interest | $214.0K | $669.0K |
| Lease liabilities arising from obtaining right-of-use assets | $2.2M | $1.1M |
No quarter-by-quarter statement was filed.
Corporate structure
Cue Biopharma, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Cue Biopharma, Inc.
- Mark E. Strome Filed SCHEDULE 13G/A on Cue Biopharma, Inc., latest Oct 8, 2026 (2 filings since May 16, 2025)
- Shao-Lee Lin Filed SCHEDULE 13D on Cue Biopharma, Inc., latest Aug 21, 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Cue Biopharma, Inc., latest Aug 14, 2026
- Bleichroeder LP Filed SCHEDULE 13G/A on Cue Biopharma, Inc., latest Mar 21, 2025 (3 filings since Mar 11, 2024)
- Slate Path Capital LP Filed SCHEDULE 13G/A on Cue Biopharma, Inc., latest Feb 14, 2025 (3 filings since Nov 18, 2022)
- BlackRock Filed SC 13G on Cue Biopharma, Inc., latest Feb 7, 2024 (4 filings since Feb 3, 2022)
- State Street Corporation Filed SC 13G/A on Cue Biopharma, Inc., latest Feb 3, 2023 (2 filings since Feb 10, 2022)
- Nantahala Capital Management, LLC Filed SC 13G/A on Cue Biopharma, Inc., latest Dec 2, 2022 (2 filings since Feb 14, 2022)
- Corriente Advisors, LLC Filed SC 13G/A on Cue Biopharma, Inc., latest Feb 14, 2022
- Cue Biopharma, Inc. Cambridge, Massachusetts, United States
- Cue Biopharma Securities Corp. Subsidiary · Massachusetts, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Cue Biopharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $3.9M6 Dec 31, 2025 | $4.2M6 Dec 31, 2024 | −6.0% |
| Accumulated depreciation | $3.7M6 Dec 31, 2025 | $3.7M6 Dec 31, 2024 | −0.5% |
| Property and equipment, net | $241.0K6 Dec 31, 2025 | $471.0K6 Dec 31, 2024 | −48.8% |
| Operating-lease assets (leased space) | $4.1M6 Dec 31, 2025 | $4.4M6 Dec 31, 2024 | −6.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $27.1M6 Dec 31, 2025 | $22.5M6 Dec 31, 2024 | +20.8% |
| Debt securities available for sale | $011 Dec 31, 2024 | $011 Dec 31, 2023 |
Properties, in its own words
Our principal office is located in Boston, Massachusetts. In March 2022, we entered into a License Agreement pursuant to which we relocated our corporate headquarters from Cambridge, Massachusetts to Boston, Massachusetts. We currently lease approximately 13,000 square feet of office and laboratory space under a lease that expires in April 2028. We use this space as our principal executive offices and for general office, research and development, and laboratory uses. We also lease additional laboratory space consisting of one procedure and two holding rooms under a lease that expires in July 2026. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.
Item 2 of the 10-K filed Mar 16, 2026.5
Leadership
Who has led Cue Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
20202025
- Chief executive officerShao-Lee Lin May 7, 2026 to now14
- Chief executive officerUsman Azam Oct 2, 2025 to May 7, 202615
- Chief executive officerDaniel R. Passeri Dec 27, 2017 to Oct 2, 202516
- PresidentAnish Suri Oct 7, 2019 to Jun 7, 202417
- PresidentDaniel R. Passeri Dec 27, 2017 to Jun 25, 201916
- Chief financial officerJames M. Ahlers Aug 3, 2026 to now18
- Chief financial officerKerri-Ann Millar Aug 25, 2020 to Aug 3, 202619
- Chief financial officerGary Alan Schuman Dec 27, 2017 to Dec 27, 201720
Board members and other officers (32)
- VP, Prin. Accounting OfficerMichael Vincent Meluzio Jun 11, 2026 to now21
- Chief Medical OfficerDominique Christian Borie Jul 15, 2026 to now22
- CHIEF BUSINESS OFFICERLucinda Warren Sep 5, 2024 to now23
- Chief Medical OfficerMatteo Levisetti Jan 19, 2023 to now24
- Chief Business OfficerPatricia Nasshorn Jan 4, 2022 to Feb 21, 202325
- VP-FinanceKerri-Ann Millar May 11, 2018 to Feb 12, 202026
- Chief Scientific OfficerAnish Suri May 16, 2018 to Mar 8, 201927
- SVP and Chief Business OfficerBethany Mancilla Aug 2, 2018 to Mar 8, 201928
- Chief Medical OfficerKenneth Pienta Dec 27, 2017 to Mar 29, 202229
- EVP, Head of ImmunologyRodolfo Chaparro Dec 27, 2017 to Jul 25, 201830
- EVP, Head of R&DRonald D. Seidel Iii. Dec 27, 2017 to Jul 25, 201831
- Board memberShao-Lee Lin May 7, 2026 to now14
- Board memberViola Mong Meehan Jun 2, 2026 to now32
- Board memberDaniel A. Camardo Jun 8, 2026 to now33
- Board memberPasha Sarraf Mar 12, 2025 to now34
- Board memberJill Marie Church Jun 6, 2025 to now35
- Board memberUsman Azam Oct 2, 2025 to now15
- Board memberPatrick Verheyen Apr 13, 2023 to now36
- Board memberPamela Garzone Apr 21, 2023 to now37
- Board memberTamar D. Howson Sep 18, 2020 to Jan 5, 202338
- Board memberAaron G.l. Fletcher Oct 7, 2019 to Jan 5, 202339
- Board memberFrederick W. Driscoll Jun 27, 2018 to Jan 3, 202540
- Board memberFrank Morich Aug 2, 2018 to now41
- Board memberAnthony Digiandomenico Dec 27, 2017 to Jan 4, 201942
- Board memberBarry J. Simon Dec 27, 2017 to Jan 6, 202143
- Board memberCameron Gray Dec 27, 2017 to Jun 16, 202244
- Board memberChristopher A. Marlett Dec 27, 2017 to Jan 6, 202045
- Board memberDaniel R. Passeri Dec 27, 2017 to now16
- Board memberPeter A. Kiener Dec 27, 2017 to now46
- Board memberSteven L. McKnight Dec 27, 2017 to Jan 6, 202047
- General counselSumita Ray Jun 11, 2026 to now48
- General counselColin Sandercock Dec 27, 2017 to now49
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Cue Biopharma Securities Corp. Massachusetts4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Imagen Biopharma, Inc.Jun 19, 2015 to Jun 19, 20153
Timeline
- Sep 21, 20268-K Regulation FD disclosure; Other events52
- Aug 14, 20268-K Results of operations53
- Aug 3, 20268-K Executive or director change54
- Jul 10, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change55
- Jun 3, 20268-K Executive or director change; Shareholder vote56
- Jun 2, 20268-K Executive or director change; Other events57
- May 14, 20268-K Financial statements and exhibits58
- May 7, 2026New chief executive Shao-Lee Lin becomes CEO14
- May 1, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change59
- Apr 22, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed60
- Apr 13, 20268-K Shareholder vote61
- Apr 7, 20268-K Other events62
- Mar 27, 20268-K Executive or director change63
- Oct 2, 2025New chief executive Usman Azam becomes CEO15
- Dec 27, 2017New chief executive Daniel R. Passeri becomes CEO16
Calendar
Coming up
- Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($2.10) a share, on Nov 12, 2025.64
When it reported results
- Aug 14, 2026Reported quarterly or annual results53
- Mar 16, 2026Reported quarterly or annual results65
- Nov 12, 2025Reported quarterly or annual results66
- Aug 12, 2025Reported quarterly or annual results67
- May 12, 2025Reported quarterly or annual results68
- Apr 15, 2025Reported quarterly or annual results69
- Mar 31, 2025Reported quarterly or annual results70
- Nov 14, 2024Reported quarterly or annual results71
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
296 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 133 insider forms, 19 large holders, 3 private raises, 71 other. The latest 20:
- Oct 14, 20264 EDGAR
- Oct 14, 20264 EDGAR
- Oct 14, 20264 EDGAR
- Oct 13, 2026144 EDGAR
- Oct 13, 2026144 EDGAR
- Oct 8, 2026SCHEDULE 13G/A EDGAR
- Sep 21, 20268-K EDGAR
- Aug 28, 20264/A EDGAR
- Aug 28, 20264/A EDGAR
- Aug 21, 2026SCHEDULE 13D EDGAR
- Aug 20, 2026EFFECT EDGAR
- Aug 18, 2026CORRESP EDGAR
- Aug 17, 20264 EDGAR
- Aug 17, 20264 EDGAR
- Aug 17, 2026UPLOAD EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
18 open-market trades by officers, directors and large owners since October 2021: 8 buys and 10 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Sale | 5,628 | $30.09 | $169.3K | Form 4 |
| Aug 13, 2026 | Lin Shao-LeeChief Executive Officer | Sale | 18,258 | $28.62 | $522.6K | Form 4 |
| Aug 13, 2026 | Ray SumitaChief Legal Compliance Officer | Sale | 8,829 | $30.09 | $265.6K | Form 4 |
| Aug 12, 2026 | Lin Shao-LeeChief Executive Officer | Sale | 40,000 | $27.10 | $1.1M | Form 4 |
| Dec 30, 2025 | Sarraf PashaDirector | Buy | 323,857 | $0.31 | $99.7K | Form 4 |
| Dec 16, 2024 | PASSERI DANIEL RCHIEF EXECUTIVE OFFICER | Buy | 30,000 | $1.03 | $30.9K | Form 4 |
| Aug 25, 2023 | Suri AnishPRESIDENT AND CSO | Buy | 4,000 | $2.76 | $11.0K | Form 4 |
| Aug 14, 2023 | PASSERI DANIEL RCHIEF EXECUTIVE OFFICER | Buy | 3,000 | $2.86 | $8.6K | Form 4 |
| Mar 23, 2023 | Kiener Peter ADirector | Sale | 9,325 | $3.28 | $30.6K | Form 4 |
| May 27, 2022 | Morich FrankDirector | Buy | 28,000 | $3.75 | $105.0K | Form 4 |
| May 24, 2022 | Fletcher Aaron G.L.Director | Buy | 55,000 | $3.34 | $183.7K | Form 4 |
| May 23, 2022 | Fletcher Aaron G.L.Director | Buy | 150,000 | $3.52 | $528.0K | Form 4 |
| Mar 31, 2022 | Fletcher Aaron G.L.Director | Buy | 735,000 | $4.76 | $3.5M | Form 4 |
| Nov 16, 2021 | Kiener Peter ADirector | Sale | 1,361 | $18.02 | $24.5K | Form 4 |
| Nov 15, 2021 | Kiener Peter ADirector | Sale | 18,815 | $17.92 | $337.2K | Form 4 |
| Nov 15, 2021 | Suri AnishPRESIDENT AND CSO | Sale | 8,000 | $18.05 | $144.4K | Form 4 |
| Nov 11, 2021 | Suri AnishPRESIDENT AND CSO | Sale | 20,000 | $15.07 | $301.4K | Form 4 |
| Oct 1, 2021 | Millar Kerri-AnnCHIEF FINANCIAL OFFICER | Sale | 1,251 | $14.21 | $17.8K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Mark E. StromeSCHEDULE 13G/A, 2 filings May 16, 2025 to Oct 8, 202672
- Shao-Lee LinSCHEDULE 13D, 1 filing Aug 21, 202673
- DRIEHAUS CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Aug 14, 202674
- Bleichroeder LPSCHEDULE 13G/A, 3 filings Mar 11, 2024 to Mar 21, 202575
- Slate Path Capital LPSCHEDULE 13G/A, 3 filings Nov 18, 2022 to Feb 14, 202576
- BlackRockSC 13G, 4 filings Feb 3, 2022 to Feb 7, 202477
- State Street CorporationSC 13G/A, 2 filings Feb 10, 2022 to Feb 3, 202378
- Nantahala Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2022 to Dec 2, 202279
- Corriente Advisors, LLCSC 13G/A, 1 filing Feb 14, 202280
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $110.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2026 | $80.0M | $80.0M |
| 2022 | $30.0M | $30.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Jul 13, 2026Raised $50 million in a private offering of equity50 Form D: 4 investors so far Form D
- May 4, 2026Raised $30 million in a private offering of securities51 Form D: 118 investors so far Form D
- Nov 16, 2022Raised $30 million in a private offering of equity81 Form D: 64 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Cue Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCue Biopharma, Inc.1
- CIK0001645460
- Employer ID (EIN)47-33245775
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address100 Chestnut Street, Suite 300, Somerville, MA 021431
- Phone617-949-26801
- Shares outstanding7,264,414 as of Aug 12, 202613
- Public float$52.0M as of Jun 30, 20255
- AuditorRSM US LLP, Boston, Massachusetts PCAOB ID 49; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceJun 19, 20151
- Filings552 in all: 4 (214), 8-K (82), 3 (36), 10-Q (26), CORRESP (15), UPLOAD (15), SC 13G (13), 424B5 (12)1
All 45 form types
DEFA14A (12), DEF 14A (11), S-8 (11), 10-K (9), EFFECT (9), SC 13G/A (9), S-3 (7), 4/A (6), D (6), PRE 14A (6), S-1/A (6), 144 (5), SCHEDULE 13G/A (5), 10-K/A (4), ARS (4), 424B3 (3), 5 (2), 8-K/A (2), CT ORDER (2), POS AM (2), S-1 (2), 10-Q/A (1), 3/A (1), 424B1 (1), 424B7 (1), 8-A12B (1), CERT (1), D/A (1), FWP (1), POSASR (1), S-1MEF (1), S-3/A (1), S-3ASR (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 16, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) May 21, 2026
Latest 8-K (8-K) Sep 21, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | CUE | Nasdaq |
From the cover page of the 10-K filed Mar 16, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Cue Biopharma, Inc. names in Item 1A of its 10-K filed Mar 16, 2026: 63 risks under these headings, as written.5
- Risks Related to Our Business
- Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
- We are a clinical-stage biopharmaceutical company, have no history of generating commercial revenue, have a history of operating losses and may never achieve or maintain profitability.
- We currently do not have, and may never develop, any FDA-approved or commercialized products.
- We are substantially dependent on the success of our drug product candidates, and significant additional research and development and clinical testing will be required before we can potentially seek regulatory approval for or commercialize any of our drug product candidates.
- We have limited experience in conducting clinical trials and no history of commercializing biologic products, which may make it difficult to evaluate the prospects for our future viability.
- Our current or any future clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile that could inhibit or prevent regulatory approval or market acceptance of any of our drug product candidates.
- Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
- We plan to continue to seek collaborations or strategic alliances. However, we may not be able to establish such relationships, and relationships we have established may not provide the expected benefits.
- Our collaboration agreements with each of LG Chem and BI contain exclusivity provisions that restrict our research and development activities.
- We may not be successful in our efforts to identify additional drug product candidates. Due to our limited resources and access to capital, we must prioritize the development of certain drug product candidates; these decisions may prove to be wrong and may adversely affect our business.
- We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results than our drug product candidates.
The other 52 risks
- If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to identify and develop new or next generation drug product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.
- Our internal computer systems, or those used by third-party CROs, manufacturers or other contractors or consultants, may fail or suffer security breaches.
- Changes in and uncertainty surrounding U.S. and international trade policies may adversely impact our business and operating results.
- Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.
- War, terrorism, other acts of violence, or natural or manmade disasters may affect the markets in which we operate, our patients and resources required in our research and development activities.
- Risks Related to Our Reliance on Third Parties
- We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to successfully complete development of, obtain regulatory approval for, or commercialize our drug product candidates and our business could be substantially harmed.
- We rely completely on third parties to manufacture our preclinical and clinical drug supplies for our drug product candidates.
- We rely on certain sole or limited sources of supply for our drug product candidates and disruptions in the chain of supply have in the past, and may in the future, cause delays in developing, obtaining approval for, and commercializing our drug product candidates.
- Risks Related to Intellectual Property and Other Legal Matters
- If we or our licensor(s) are unable to protect our or its intellectual property, then our financial condition, results of operations and the value of our technology and potential products could be adversely affected.
- If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and potential products could be adversely affected.
- If we fail to comply with our obligations in the agreements under which we license development or commercialization rights to products or technology from third parties, we could lose license rights that are important to our business.
- If we are unable to patent and protect the intellectual property used in our potential products, others may be able to copy our innovations, which may impair our ability to compete effectively in our markets.
- Litigation or third-party claims of intellectual property infringement or challenges to the validity of our anticipated patents would require us to use resources to protect our technology and may prevent or delay our development, regulatory approval or commercialization of our drug product candidates.
- Patent terms may be inadequate to protect our competitive position on our drug product candidates for an adequate amount of time.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug product candidates.
- Risks Related to Government Regulation
- Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any of our drug product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our drug product candidates, and our ability to generate revenue will be materially impaired.
- We are subject to regulation in respect of our research and federal funding.
- Failure to obtain marketing approval in foreign jurisdictions would prevent any of our drug product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.
- We may seek orphan drug designation for one or more of our drug product candidates, but even if such designation is granted, we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity that prevents the FDA or the EMA from approving other competing products.
- If approved, our drug product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
- We may seek fast track designation or breakthrough therapy and priority review programs for our drug product candidates. Even if our drug product candidates receive one or more of these designations, the product candidate may not be subject to a faster review process nor does any such designation assure approval of our drug product candidates.
- We may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our drug product candidates. If we are not able to use such pathways, we may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we receive them at all. In addition, even if an accelerated approval pathway is available to us, it may not lead to expedited approval of our drug product candidates, or approval at all.
- We may in the future conduct clinical trials for certain of our drug product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations and the conduct of trials outside the United States could subject us to additional delays and expense.
- To obtain the necessary approval of our potential products, as a precondition, we will need to conduct various preclinical and clinical tests, all of which will be costly and time consuming, and may not provide results that will allow us to seek regulatory approval.
- Even if we, or any collaborators we may have, obtain marketing approvals for any of our drug product candidates, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.
- If we receive regulatory approval for any product candidate, we will be subject to ongoing obligations and continuing regulatory review, which may result in significant additional expense. Our drug product candidates, if approved, could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drug product candidates, when and if approved.
- Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.
- Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program, progress development efficiently, and secure approval of our product candidates in a timely manner, which would negatively impact our business.
- Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
- If commercial third-party payors or government payors fail to provide coverage or adequate reimbursement, our revenue and prospects for profitability would be harmed.
- Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug product candidates and affect the prices we may obtain for any products that are approved in the United States or foreign jurisdictions.
- The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if approved.
- Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs.
- Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- We are subject to stringent federal and state privacy laws, information security laws, regulations, policies, and contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain drug product candidates outside of the United States and require us to develop and implement costly compliance programs.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- Risks Related to Our Financial Results, Our Need for Financing and Owning Our Common Stock
- We anticipate future losses and negative cash flow, and it is uncertain if or when we will become profitable.
- We will need substantial additional financing to support our growth and ongoing operations. Additional capital may be difficult to obtain, restrict our operations, require us to relinquish rights to our technologies or drug product candidates, encumber our assets and result in ongoing debt service cost, or result in additional dilution to our stockholders.
- We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
- Our stock price can be volatile and fluctuate significantly, and our stockholders may have difficulty selling their shares and/or suffer substantial losses.
- If we fail to regain compliance with the continued listing requirements of Nasdaq, our common stock may be delisted and the price and liquidity of our common stock and our ability to access the capital markets could be negatively impacted.
- We may be subject to securities litigation, which is expensive and could divert management attention.
- If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the price of our securities and trading volume could decline.
- We have not paid dividends in the past and have no immediate plans to pay dividends.
- Our ability to use net operating loss carryforwards and research and development tax credits to reduce future tax payments may be limited or restricted.
- We incur significant costs as a result of being a public company and our management is required to devote substantial time to meet compliance obligations.
- Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
- Our Certificate of Incorporation provides, subject to certain exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders.
- If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities may decrease.
- If a significant number of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is performing well.
Legal proceedings
We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARUsman Azam, Chief executive officer
- 16
- 17SEC EDGARAnish Suri, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26SEC EDGARKerri-Ann Millar, VP-Finance
- 27SEC EDGARAnish Suri, Chief Scientific Officer
- 28
- 29
- 30
- 31
- 32SEC EDGARViola Mong Meehan, Board member
- 33SEC EDGARDaniel A. Camardo, Board member
- 34SEC EDGARPasha Sarraf, Board member
- 35SEC EDGARJill Marie Church, Board member
- 36SEC EDGARPatrick Verheyen, Board member
- 37SEC EDGARPamela Garzone, Board member
- 38SEC EDGARTamar D. Howson, Board member
- 39SEC EDGARAaron G.l. Fletcher, Board member
- 40SEC EDGARFrederick W. Driscoll, Board member
- 41SEC EDGARFrank Morich, Board member
- 42SEC EDGARAnthony Digiandomenico, Board member
- 43SEC EDGARBarry J. Simon, Board member
- 44SEC EDGARCameron Gray, Board member
- 45SEC EDGARChristopher A. Marlett, Board member
- 46SEC EDGARPeter A. Kiener, Board member
- 47SEC EDGARSteven L. McKnight, Board member
- 48SEC EDGARSumita Ray, General counsel
- 49SEC EDGARColin Sandercock, General counsel
- 50
- 51
- 52
- 53SEC EDGARResults of operations
- 54SEC EDGARExecutive or director change
- 55
- 56
- 57
- 58SEC EDGARFinancial statements and exhibits
- 59
- 60
- 61SEC EDGARShareholder vote
- 62SEC EDGAROther events
- 63SEC EDGARExecutive or director change
- 64NasdaqNasdaq calendar
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81